| 8.16 0 (0%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.74 | 1-year : | 11.38 |
| Resists | First : | 8.34 | Second : | 9.74 |
| Pivot price | 8.15 |
|||
| Supports | First : | 7.97 | Second : | 7.75 |
| MAs | MA(5) : | 8.1 |
MA(20) : | 8.1 |
| MA(100) : | 4.15 |
MA(250) : | 2.59 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 68.9 |
D(3) : | 62.9 |
| RSI | RSI(14): 66.6 | |||
| 52-week | High : | 8.34 | Low : | 0.83 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RGLS ] has closed below upper band by 49.8%. Bollinger Bands are 75.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.17 - 8.2 | 8.2 - 8.24 |
| Low: | 8.06 - 8.1 | 8.1 - 8.15 |
| Close: | 8.09 - 8.16 | 8.16 - 8.22 |
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Wed, 02 Jul 2025
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Wed, 25 Jun 2025
Novartis completes acquisition of Regulus Therapeutics and initiates Nasdaq delisting - Investing.com
Wed, 04 Jun 2025
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha
Thu, 08 May 2025
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PR Newswire
Wed, 30 Apr 2025
Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion (NVS, RGLS) - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 82.8 (%) |
| Shares Short | 1,760 (K) |
| Shares Short P.Month | 1,910 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.3 % |
| Return on Equity (ttm) | -53.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.53 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -12 |
| PEG Ratio | 0 |
| Price to Book value | 7.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|